MAFA
DGX icon

MJT & Associates Financial Advisory’s Quest Diagnostics DGX Stock Holding History

MJT & Associates Financial Advisory’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22
Closed -$4.31K – 473
2026
Q1 		$4.31K Hold
22
– – ﹤0.01% 284
2025
Q4 		$3.82K Buy
22
+2
+10% +$364 ﹤0.01% 325
2025
Q3 		$3.81K Hold
20
– – ﹤0.01% 333
2025
Q2 		$3.59K Hold
20
– – ﹤0.01% 344
2025
Q1 		$3.38K Buy
+20
New +$3.29K ﹤0.01% 354

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

MJT & Associates Financial Advisory's DGX Position: Q2 2026 in Review

MJT & Associates Financial Advisory sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 22 shares — an estimated $4.31K sold.

MJT & Associates Financial Advisory first reported a position in DGX in Q1 2025 and held it in 5 quarters. The position peaked at $4.31K in Q1 2026. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • MJT & Associates Financial Advisory reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • MJT & Associates Financial Advisory sold 22 Quest Diagnostics shares in Q2 2026, an estimated $4.31K.
  • MJT & Associates Financial Advisory first reported a position in Quest Diagnostics in Q1 2025 and held it in 5 quarters.
  • MJT & Associates Financial Advisory's Quest Diagnostics position peaked at $4.31K in Q1 2026.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q2 2026, filed 6 Jul 2026.